Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gastric Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 48 articles: HTML format

Single Articles

June 2024
1. NAGEL G, Chen J, Jaensch A, Skodda L, et al
   Long-term exposure to air pollution and incidence of gastric and the upper aerodigestive tract cancers in a pooled European cohort: The ELAPSE project.
   Int J Cancer. 2024;154:1900-1910.
   PubMed     Abstract available
   
   
   December 2023
2. SASAHARA M, Kanda M, Tanaka C, Shimizu D, et al
   Therapeutic antibody targeting natriuretic peptide receptor 1 inhibits gastric cancer growth via BCL-2-mediated intrinsic apoptosis.
   Int J Cancer. 2023 Dec 27. doi: 10.1002/ijc.34831.
   PubMed     Abstract available
   
   
   
3. ZHANG Q, Zhou Y, Song L, Fang W, et al
   China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study.
   Int J Cancer. 2023;153:1885-1893.
   PubMed     Abstract available
   
   
   November 2023
4. GOETZE TO, Stein A, Lorenzen S, Habibzada T, et al
   Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
   Int J Cancer. 2023;153:1726-1733.
   PubMed     Abstract available
   
   
   
5. RIJKEN A, Pape M, Simkens GA, de Hingh IHJT, et al
   Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival.
   Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34780.
   PubMed     Abstract available
   
   
   October 2023
6. FAN XH, Zhang Y, Wang P, Song QQ, et al
   A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening.
   Int J Cancer. 2023 Oct 16. doi: 10.1002/ijc.34739.
   PubMed     Abstract available
   
   
   September 2023
7. LLACH J, Salces I, Guerra A, Penas B, et al
   Endoscopic surveillance for familial intestinal gastric cancer in low-incidence areas: An effective strategy.
   Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34714.
   PubMed     Abstract available
   
   
   
8. PALOMAR-CROS A, Straif K, Romaguera D, Aragones N, et al
   Consumption of aspartame and other artificial sweeteners and risk of cancer in the Spanish multicase-control study (MCC-Spain).
   Int J Cancer. 2023;153:979-993.
   PubMed     Abstract available
   
   
   August 2023
9. CHENG L, Chang Y, Xia Z, Liu Y, et al
   Remote modulation of WWOX by an intronic variant associated with survival of Chinese gastric cancer patients.
   Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34703.
   PubMed     Abstract available
   
   
   
10. CAO F, Sun H, Yang Z, Bai Y, et al
    Multiple approaches revealed MGc80-3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line.
    Int J Cancer. 2023 Aug 6. doi: 10.1002/ijc.34677.
    PubMed     Abstract available
    
    
    July 2023
11. GOETZE TO, Hofheinz RD, Gaiser T, Schmalenberg H, et al
    Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
    Int J Cancer. 2023;153:153-163.
    PubMed     Abstract available
    
    
    March 2023
12. GHASEMI-KEBRIA F, Semnani S, Fazel A, Etemadi A, et al
    Esophageal and gastric cancer incidence trends in Golestan, Iran: an age-period-cohort analysis 2004-2018.
    Int J Cancer. 2023 Mar 21. doi: 10.1002/ijc.34518.
    PubMed     Abstract available
    
    
    
13. KUIJPER SC, Pape M, Haj Mohammad N, van Voorthuizen T, et al
    SOURCE beyond first-line: A survival prediction model for patients with metastatic esophagogastric adenocarcinoma after failure of first-line palliative systemic therapy.
    Int J Cancer. 2023;152:1202-1209.
    PubMed     Abstract available
    
    
    
14. XI J, Li Y, Zhang H, Bai Z, et al
    Dynamic variations of the gastric microbiota: Key therapeutic points in the reversal of Correa's cascade.
    Int J Cancer. 2023;152:1069-1084.
    PubMed     Abstract available
    
    
    
15. MOHRING C, Manczak A, Timotheou A, Sadeghlar F, et al
    Perioperative Therapy with Flot4 Significantly Increases Survival in Patients with Gastroesophageal and Gastric Cancer in A Large Real-World Cohort.
    Int J Cancer. 2023 Mar 15. doi: 10.1002/ijc.34511.
    PubMed     Abstract available
    
    
    
16. KUIJPER SC, Pape M, Vissers PAJ, Jeene PM, et al
    Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study.
    Int J Cancer. 2023 Mar 1. doi: 10.1002/ijc.34488.
    PubMed     Abstract available
    
    
    February 2023
17. PAPE M, Kuijper SC, Vissers PAJ, Ruurda JP, et al
    Conditional relative survival in non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study.
    Int J Cancer. 2023 Feb 25. doi: 10.1002/ijc.34480.
    PubMed     Abstract available
    
    
    
18. ZHANG P, Gu Y, Wang J, Lv K, et al
    Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer.
    Int J Cancer. 2023 Feb 17. doi: 10.1002/ijc.34474.
    PubMed     Abstract available
    
    
    
19. LIU T, Bai Y, Lin X, Li W, et al
    First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
    Int J Cancer. 2023;152:749-760.
    PubMed     Abstract available
    
    
    December 2022
20. CHEN M, Chen K, Hou H, Li W, et al
    Incidence and mortality trends in gastric cancer in the United States, 1992-2019.
    Int J Cancer. 2022 Dec 23. doi: 10.1002/ijc.34415.
    PubMed     Abstract available
    
    
    November 2022
21. YANG H, Wang XK, Wang JB, Zhao FH, et al
    Combined risk factors and risk of upper gastrointestinal cancer mortality in the Linxian general population.
    Int J Cancer. 2022;151:1462-1473.
    PubMed     Abstract available
    
    
    August 2022
22. LEE SH, Lee Y, Jang HJ
    Deep learning captures selective features for discrimination of microsatellite instability from pathologic tissue slides of gastric cancer.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34251.
    PubMed     Abstract available
    
    
    June 2022
23. QIAN Y, Zhai E, Chen S, Liu Y, et al
    Single-cell RNA-seq dissecting heterogeneity of tumor cells and comprehensive dynamics in tumor microenvironment during lymph nodes metastasis in gastric cancer.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34172.
    PubMed     Abstract available
    
    
    
24. WANG S, Zheng R, Arnold M, Abnet C, et al
    Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype.
    Int J Cancer. 2022 Jun 9. doi: 10.1002/ijc.34158.
    PubMed     Abstract available
    
    
    April 2022
25. COLLATUZZO G, Etemadi A, Sotoudeh M, Nikmanesh A, et al
    Meat consumption and risk of esophageal and gastric cancer in the Golestan Cohort Study, Iran.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34056.
    PubMed     Abstract available
    
    
    March 2022
26. WU F, Yang L, Hao Y, Zhou B, et al
    Oral and gastric microbiome in relation to gastric intestinal metaplasia.
    Int J Cancer. 2022;150:928-940.
    PubMed     Abstract available
    
    
    November 2021
27. QU Y, Wang X, Bai S, Niu L, et al
    The effects of TNF-alpha/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
    Int J Cancer. 2021 Nov 11. doi: 10.1002/ijc.33873.
    PubMed     Abstract available
    
    
    
28. PEREIRA C, Park JH, Campelos S, Gullo I, et al
    Comparison of East-Asia and West-Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness.
    Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33872.
    PubMed     Abstract available
    
    
    
29. HOGNER A, Al-Batran SE, Siveke JT, Lorenz M, et al
    Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: a randomized phase-II study - the PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
    Int J Cancer. 2021 Nov 6. doi: 10.1002/ijc.33864.
    PubMed     Abstract available
    
    
    
30. GU J, Xie S, Wang S, Xue L, et al
    Surveillance of premalignant gastric cardia lesions: A population-based prospective cohort study in China.
    Int J Cancer. 2021;149:1639-1648.
    PubMed     Abstract available
    
    
    October 2021
31. YANG Y, Long J, Wang C, Blot WJ, et al
    Prospective Study of Oral Microbiome and Gastric Cancer Risk Among Asian, African American and European American Populations.
    Int J Cancer. 2021 Oct 18. doi: 10.1002/ijc.33847.
    PubMed     Abstract available
    
    
    September 2021
32. CABASAG CJ, Arnold M, Pineros M, Morgan E, et al
    Population-based cancer staging for oesophageal, gastric, and pancreatic cancer 2012-2014: International Cancer Benchmarking Partnership SurvMark-2.
    Int J Cancer. 2021;149:1239-1246.
    PubMed     Abstract available
    
    
    August 2021
33. KAWAI S, Wang C, Lin Y, Sasakabe T, et al
    Lifetime incidence risk for gastric cancer in the Helicobacter pylori-infected and uninfected population in Japan: A Monte Carlo simulation study.
    Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33773.
    PubMed     Abstract available
    
    
    June 2021
34. JAYASEKARA H, MacInnis RJ, Lujan-Barroso L, Mayen-Chacon AL, et al
    Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies.
    Int J Cancer. 2021;148:2759-2773.
    PubMed     Abstract available
    
    
    May 2021
35. HOFHEINZ RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, et al
    Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study G
    Int J Cancer. 2021 May 21. doi: 10.1002/ijc.33696.
    PubMed     Abstract available
    
    
    
36. COLLATUZZO G, Pelucchi C, Negri E, Lopez-Carrillo L, et al
    Exploring the interactions between Hp infection and other risk factors of gastric cancer: a pooled analysis in the Stomach cancer Pooling (StoP) Project.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33678.
    PubMed     Abstract available
    
    
    April 2021
37. NESS-JENSEN E, Bringeland EA, Mattsson F, Mjones P, et al
    Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective population-based nested case-control study.
    Int J Cancer. 2021;148:1879-1886.
    PubMed     Abstract available
    
    
    
38. LIU C, Song K, Hu Q, Hu C, et al
    Having gastroesophageal cancer is associated with increased risk of severe COVID-19-related events in patients with digestive tract cancer: A multicenter, retrospective, cohort study.
    Int J Cancer. 2021;148:1789-1793.
    PubMed    
    
    
    January 2021
39. WATANABE Y, Oikawa R, Kodaka Y, Sato Y, et al
    Cancer-related genetic variants of Helicobacter pylori strains determined using gastric wash-based whole-genome analysis with single-molecule real-time technology.
    Int J Cancer. 2021;148:178-192.
    PubMed     Abstract available
    
    
    December 2020
40. KATAGIRI R, Goto A, Shimazu T, Yamaji T, et al
    Dietary fiber intake and risk of gastric cancer: the Japan Public Health Center-based prospective study.
    Int J Cancer. 2020 Dec 21. doi: 10.1002/ijc.33450.
    PubMed     Abstract available
    
    
    
41. CHOI J, Jia G, Wen W, Long J, et al
    Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants.
    Int J Cancer. 2020;147:3416-3423.
    PubMed     Abstract available
    
    
    
42. EL KHADIR M, Boukhris Alaoui S, Benajah DA, Ibrahimi SA, et al
    VacA genotypes and cagA-EPIYA-C motifs of Helicobacter pylori and gastric histopathological lesions.
    Int J Cancer. 2020;147:3206-3214.
    PubMed     Abstract available
    
    
    November 2020
43. LI B, Cheung KS, Wong IY, Leung WK, et al
    Calcium channel blockers are associated with lower gastric cancer risk: a territory-wide study with propensity score analysis.
    Int J Cancer. 2020 Nov 5. doi: 10.1002/ijc.33379.
    PubMed     Abstract available
    
    
    
44. CANZIAN F, Rizzato C, Obazee O, Stein A, et al
    Genetic polymorphisms in the cag pathogenicity island of Helicobacter pylori and risk of stomach cancer and high-grade premalignant gastric lesions.
    Int J Cancer. 2020;147:2437-2445.
    PubMed     Abstract available
    
    
    
45. LORENZEN S, Knorrenschild JR, Pauligk C, Hegewisch-Becker S, et al
    Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC).
    Int J Cancer. 2020;147:2493-2502.
    PubMed     Abstract available
    
    
    
46. GARCIA RODRIGUEZ LA, Soriano-Gabarro M, Vora P, Cea Soriano L, et al
    Low-dose aspirin and risk of gastric and oesophageal cancer: A population-based study in the United Kingdom using The Health Improvement Network.
    Int J Cancer. 2020;147:2394-2404.
    PubMed     Abstract available
    
    
    October 2020
47. LV K, Li R, Cao Y, Gu Y, et al
    LAG-3 expression associates with poor prognosis and immunoevasive contexture in EBV-positive and MLH1-defective gastric cancer patients.
    Int J Cancer. 2020 Oct 26. doi: 10.1002/ijc.33358.
    PubMed     Abstract available
    
    
    August 2020
48. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.